跳至主要内容
临床试验/NCT03195231
NCT03195231Unknown4 期

Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.

Beijing Hospital0 个研究点目标入组 120 人开始时间: 2017年6月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
120
主要终点
the change of depression from baseline to 12 weeks

研究概览

简要总结

Depression is one of the most important nonmotor features of idiopathic PD(Parkinson's disease )which may not just interfere with the motor symptoms of PD but can also cause immense personal suffering as well as decreased quality of life with increased disability and caregiver burden. However,there is little hard evidence to guide clinical treatment. Although some newer dopamine agonists also have antidepressive effect, the use of tricyclic or nontricyclic antidepressants is frequently required.However, the side-effects of these agents may also worsen some preexisting nonmotor problems in PD. Wuling powder is a Chinese medicine which is made by cultivating Xylariasp mycelium using submerged fermentation technology. Xylariasp is the fungus sclerotia which grow in termite nests. Wuling powder is mainly used to soothe nerves and anti-insomnia in clinical. The antidepressant effect of Wuling powder has been confirmed in clinical, but not in the patients of Parkinson's disease. Therefore, the investigators design a randomized, double-blind, placebo-controlled study to evaluate the antidepressant effect of Wuling powder in PD patients and its underlying mechanism.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of idiopathic Parkinson's disease according to the 2015 MDS(Movement Disorder Society)-PD criterion
  • •Hoehn-Yahr stage: 1-3
  • •Under steady therapy of antiparkinsonian drugs for at least 28 days
  • •MMSE(Mini-Mental State Examination)≥24
  • •Neither use antidepressant drugs nor antipsychotic drugs within 4 weeks
  • •Signed informed consent

排除标准

  • •Have other psychotic symptoms
  • •Suicide ideation or behavior
  • •Severe cognitive impairment,chronic organs failure,malignant tumors
  • •Glutamic-pyruvic transaminase or glutamic oxalacetic transaminase≥1.5 times of the high normal range or white blood cell<4*10^9/L or serum creatinine>84umol/L
  • •Pregnancy or lactation period
  • •Participant in other trials or have taken other experimental drugs within 90 days
  • •Allergic to fungal food or fungal drugs

研究组 & 干预措施

Wuling Powder Group

Experimental

Take Wuling Powder 3 times a day,3 pills each time for 12 weeks

干预措施: Wuling Powder (Drug)

Placebo Group

Placebo Comparator

Take placebo drug which cannot be distinguished from the experimental drug 3 times a day,3 pills each time for 12 weeks

干预措施: Placebo (Drug)

结局指标

主要结局

the change of depression from baseline to 12 weeks

时间窗: 12 weeks after treatment

the change of depression from baseline to 12 weeks,as assessed with the use of HAMD(Hamilton Depression Scale)

次要结局

未报告次要终点

研究者

发起方
Beijing Hospital
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Wen Su

Clinical professor and Principal investigator

Beijing Hospital

相似试验